Key Laboratory of Combined Multi-organ Transplantation, Department of Hepatobiliary and Pancreatic Surgery Hospital, Ministry of Public Health, Zhejiang University School of Medicine, Qingchun Road #79, Hangzhou, China.
Braz J Infect Dis. 2011 Sep-Oct;15(5):486-9. doi: 10.1016/s1413-8670(11)70234-3.
Nocardia infection is rare but potentially fatal. Therapy of Nocardia infection remains difficult. Linezolid, a novel oxazolidinone antibiotic, has proven to be effective, but clinical data are limited. Here we describe a case of a 45-year-old man with pulmonary N. farcinica infection following a liver transplantation. The initial therapy was trimethoprim-sulfamethoxazole, which showed no effect. According to susceptibility test, linezolid was administered with clearly improving the patient's condition. The treatment was stopped for anemia as drug related adverse event, and the therapy lasted for as long as 5 months. At the end of treatment clinical cure was confirmed and anemia reversed after discontinuation of linezolid. We also analyzed the clinical data of previously published reports by literature review, focusing on the efficacy and safety of linezolid treatment for Nocardia infection.
奴卡菌感染较为罕见,但可能致命。奴卡菌感染的治疗仍然很困难。利奈唑胺是一种新型噁唑烷酮类抗生素,已被证明有效,但临床数据有限。本文描述了 1 例肝移植术后肺部感染诺卡菌的 45 岁男性患者。初始治疗采用复方磺胺甲噁唑,但效果不佳。根据药敏试验,给予利奈唑胺治疗,患者病情明显改善。因药物相关不良反应(贫血)停药,治疗持续 5 个月。治疗结束时临床治愈,停药后贫血得到纠正。我们还通过文献复习分析了既往报道的病例资料,重点探讨了利奈唑胺治疗奴卡菌感染的疗效和安全性。